1787. The safety and efficacy of an oral penicillin rechallenge program in cancer patients – A pilot multicentre study
Session: Poster Abstract Session: Antimicrobial Stewardship: Impact of Allergy
Saturday, October 6, 2018
Room: S Poster Hall
Posters
  • ID WEEK 2018_Oral penicillin rechallenge (1).pdf (570.7 kB)
  • Background:

    Patient-reported antibiotic allergies (so-called antibiotic allergy labels [AALs]) are found in 1 in 4 cancer patients and significantly impact patient outcomes. Whilst 85% of AALs can be removed by skin testing, the role of simple point-of-care oral penicillin rechallenge in this cohort remains unknown. We report on a novel penicillin rechallenge program in cancer patients.

    Methods:

    An oral penicillin rechallenge program was implemented at Austin Health (Melb, Aus) and Peter MacCallum Cancer Centre (Melb, Aus) on the 31st of May 2017. Patients were prospectively identified by Infectious Diseases and antimicrobial stewardship (AMS) services at both sites and reviewed by the conjoint Antibiotic Allergy Service for suitability as per the criteria outlined in Figure 1. Patients underwent supervised challenge with oral penicillin VK 250mg or amoxicillin 250mg, dependent on reported index allergy, and observed for 2-hours post. Patients were followed for up to 12 months post for adverse events and antibiotic usage.

    Results:

    Twenty-nine patients underwent penicillin oral challenge between the period of 31st of May 2017 to 30th April 2018, 15 with cancer. Of those with cancer, 8 (53%) were male, median age 56 years (IQR 44, 67), 15 (100%) avoiding penicillin and 7 (47%) penicillins and cephalosporins. The penicillin/amoxicillin AAL phenotypes were “rash” in 73% (11/15) and “unknown” in 27% (4/15). Patients were challenged with penicillin VK or amoxicillin, based on their reported penicillin allergy with no positive challenges or adverse events noted in those with (n = 15) and without (n = 14) cancer. In the follow-up period, 88% (14/16) patients that were prescribed antibiotics received a narrow spectrum beta-lactam.

    Conclusion:

    A pilot penicillin oral rechallenge program was safe in cancer patients. This program serves as a future model for active “de-labelling” in carefully selected cancer patients, without formal allergy services, aiding AMS programs.

    Figure 1: Selection algorithm for oral penicillin rechallenge program

    Olivia Smibert, Bachelor of Medicine, Bachelor of Surgery1, Abby Douglas, MBBS1, Misha Devchand, BPharm2, Belinda Lambros, BSN3, Wendy Stevenson, BSN4, Monica Slavin, MBBS FRACP MD5 and Jason Trubiano, MBBS/BBioMed Sci FRACP6, (1)Infectious Diseases and Microbiology, Peter MacCallum Cancer Center, Melbourne, Australia, (2)Austin Hospital, Melbourne, Australia, (3)Peter MacCallum Cancer Center, Melbourne, Australia, (4)Austin health, Melbourne, Australia, (5)Peter MacCallum Cancer Centre, Melbourne, Australia, (6)Department of Medicine, University of Melbourne, Melbourne, Australia

    Disclosures:

    O. Smibert, None

    A. Douglas, None

    M. Devchand, None

    B. Lambros, None

    W. Stevenson, None

    M. Slavin, None

    J. Trubiano, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.